References and Related Resources
1) Radioimmunotherapy Agents: What They Are and How They
Work www.bloodline.net
2) Biodistribution and dosimetry results from a
phase III prospectively randomized controlled trial of Zevalin
radioimmunotherapy for low-grade, follicular, or transformed B-cell
non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001
Jul-Aug;39(1-2):181-94.PMID: 11418315 PubMed
3) FDA Review of Biologics License Application for IDEC Pharmaceutical ZEVALIN™ Kit -
BLA# 125019 fda.gov
- backgrounder.pdf
4) Zevalin Resource Guide zevalin.com
5) Bexxar®: Novel Radioimmunotherapy for the Treatment of Low-Grade and Transformed Low-Grade Non-Hodgkin’s Lymphoma
~ The Oncologist, Vol. 9, No. 2, 160–172, April 2004 © 2004 AlphaMed Press
theoncologist.alphamedpress.org
6) Arming antibodies, prospects and challenges chem.indiana.edu
PDF
7) Briefing Document on Bexxar submitted to FDA www.fda.gov
8) Radioimmunotherapy in the treatment
of low grade b-cell lymphoma www.cecity.com/nocr/ash2003/section3.pdf
Robert O. Dillman, M.D., Medical
Director, Hoag Cancer Center, Newport Beach, California
Radiation dosimetry results and safety
correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed
or refractory non-Hodgkin's lymphoma: combined data from 4 clinical
trials. J Nucl Med. 2003 Mar;44(3):465-74. PMID:
12621016
Relapsed or refractory NHL in patients with adequate bone marrow
reserve and <25% bone marrow involvement by NHL can be treated safely
with (90)Y-ibritumomab tiuxetan RIT on the basis of a fixed,
weight-adjusted dosing schedule. Dosimetry and pharmacokinetic results do
not correlate with toxicity.
9) Alexandra M. Levine, MD Robert S.
Mocharnuk, MD
Rituximab, Tositumomab (Bexxar), Ibritumomab (Zevalin): And the
Winner Is... Medscape.com
(free login req.)
10) Zevalin: Risk of MDS/AML
update www.fda.gov
| Zevalin_PI.pdf
"Myelodysplastic syndrome (MDS) and/or acute myelogenous
leukemia (AML) were reported in 5.2% (11/211) of patients enrolled
in clinical studies and 1.5% (8/535) of patients included in the
expanded-access trial, with median follow-up of 6.5 and 4.4 years,
respectively. Among the 19 reported cases, the median time to the
diagnosis of MDS or AML was 1.9 years following treatment with the
Zevalin therapeutic regimen; however, the cumulative incidence
continues to increase."
11) Specific Regimen
[Bexxar] Influences Risk
of Myelodysplasia After Lymphoma Treatment BloodJournal
A total of 1071 patients were enrolled
in 7 studies: 995 with relapsed/refractory low-grade NHL, ±
transformation (median, 3 prior regimens [range, 1-13
regimens]) and 76 patients with previously untreated low-grade
follicular NHL.
Median follow-up was 6 years from diagnosis and 2 years from radioimmunotherapy
(RIT) for previously treated patients, and 4.6 years from
radioimmunotherapy for previously untreated patients. tMDS/tAML
was reported in 35 (3.5%) of 995 patients (annualized incidence,
1.6%/y [95% confidence interval, 1.0%-2.0%/y]), and 52% of the
tMDS/tAML diagnoses of tMDS/tAML were confirmed in a blinded
review (annualized incidence of 1.1%/y [95% confidence interval,
0.7%-1.6%/y]).
Of the 25 cases, 10 patients (40%) were diagnosed with tMDS/tAML
prior to receiving radioimmunotherapy; 2 (8%) had no pathologic
or clinical evidence to support such a diagnosis; and 13
(52%) were confirmed to have developed tMDS/tAML following
RIT. This incidence is consistent with that expected on the
basis of patients' prior chemotherapy for NHL.
With a median follow-up approaching 5 years, no case of
tMDS/tAML has been reported in any of the 76 patients
receiving iodine I131 tositumomab as their initial therapy
(P = .011 compared with previously treated patients).
Questions for Experts
Clearance: Does the faster (Bexxar) or slower (Zevalin) clearance of these agents - and other properties of the radioisotopes -
tell us anything about relative risks and potential efficacy of these two
agents?
Comparing Sequential chemo-RIT with autologous SCT? We
believe a study comparing the following protocols would answer an
important clinical question, and would also be of interest to patients
with high risk lymphoma referred to a transplantation center: Sequential
HD chemo (with harvesting), sequenced with RIT versus Autologous
SCT
HAMA
(human anti-mouse antibodies): What is the clinical significance of developing
HAMA?
"Development of HAMA can occur after exposure to tositumomab,
especially in patients who have not received prior chemotherapy for their
disease. In this group who receive "front-line" tositumomab,
HAMA antibodies have been demonstrated in as many as 64%. In a study by
Mark S. Kaminski, from the University of Michigan, Ann Arbor, Michigan,
and colleagues,[5] 22 patients with HAMA responses to
tositumomab were studied, and 6 were found to have high titer (> 500
mg/mL) antibody. Thirteen of these patients subsequently received
rituximab. Although response rates were not reported, it is important to
note that there was no evidence of increased severity or frequency of
infusion reactions. Therefore, it seems that rituximab can be given safely
after development of HAMA responses to tositumomab."
http://www.medscape.com
Wavelength & bulk: Do the
different wavelengths (longer for Zevalin, shorter for Bexxar) and other properties of the radioisotopes make one or the other a better choice when the patient has
small or large tumors?
Wavelength/Clearance & bone marrow: Does
half life (longer for Zevalin, shorter for Bexxar) and other properties of
the radioisotopes favor one agent over another when the patient has
minimal or significant bone marrow involvement.?
Migration tenancy: Does the migration tendencies (*Zevalin to the marrow and liver/ Bexxar to the thyroid
as a few examples) favor one agent over the other in specific circumstances?
Data on Treating Refractory Disease: Is there data to tell us that one agent is a more
effective than the other for patients refractory to prior rituxan and chemotherapy? Which agent has the most data on this?
High Dose: When is high dose (HD) radioimmunotherapy indicated? Can HD radiotherapy be used outside a clinical trial in cases where it is indicated?
Lay comment: One indication seems to be in preparation for stem cell
transplants, especially when conditioning chemotherapy fails to achieve a
remission.
Extranodal: Does extranodal,
mucosal, or CNS involvement preclude the use of radioimmunotherapy?
Notes:
[A] Dosing: Bexxar, being both a gamma and beta emitter, allows doctors to
monitor the amount of radiation that actually makes it to the targeted sites. This
property allows for accurate dosing in a process called dosimetry.
"The purpose of the dosimetric step is to provide a consistent radiation dose by adjusting for the individual patient's rate of clearance of the drug. Clinical studies found that patients with high tumor burden, splenomegaly, or bone marrow involvement have a faster clearance, shorter terminal half-life, and larger volume of distribution. Patient-specific dosing, based on total body clearance, has been found to provide a consistent radiation dose, despite variable pharmacokinetics, by allowing each patient's administered activity to be adjusted for individual patient variables."
- Aetna
For detailed information on absorbed dose of Zevalin see -
fda.gov
- backgrounder.pdf
[B] Bexxar, being both a gamma and beta emitter, allows doctors to monitor the amount of radiation that actually makes it to the targeted sites. This property allows for very accurate dosing in a process called dosimetry.
Because of the gamma radiation that exits the person's body, patients who receive Bexxar need to take radiation safety precautions to prevent exposure to other people for up to ~8 days after receiving treatment.
[C] Patients receiving Bexxar may have to take SSKI or Lugol solution (iodine) before and after the administration of the hot dose to block the thyroid and prevent damage to it.
"dehalogenation of the isotope from the antibody can occur and
result in thyroid damage by the radioactive iodine." www.pharmaweek.com
[D] Because of the gamma radiation that exits the person's body,
patients who receive Bexxar need to take radiation safety precautions to prevent exposure
to other people for up to ~8 days after receiving treatment.
[E] A mouse (murine) anti-CD20+ antibody is used as the carrier of the yttrium-90 radioisotope
(Zevllin) because it's eliminated from the body faster than Rituxan. Rituxan is used as pretreatment, however. Presumably to clear peripheral blood of normal b-cells to reduce radiation exposure to normal circulating b-cells.
Clinical Trials
Accuracy: We have not yet confirmed the accuracy of all the details in
this table.
Main Sources: Lymphoma.org, IDEC, and NCI
websites
|
.gif){kind=small}